
==== Front
BMC Womens Health
BMC Womens Health
BMC Women's Health
1472-6874
BioMed Central London

3311
10.1186/s12905-024-03311-9
Research
Relation between serum sclerostin and CTRP3 levels and bone mineral density in diabetic postmenopausal women
Ahmad Inass Hassan 1
Elhamed Gbr Sally Said Abd 2
Ali El Naggar Basma Mohamed Mohamed 3
Abdelwahab Marwa Khairy 4
El-saghier Entesar Omar Ahmad 1
Mohammed Doaa Sayed 1
Mohamed Marwa Abdelmonim 2
Mohamed Maha S. 3
Ali Abd El-Rahim Marwa Mohamed M. 3
http://orcid.org/0000-0001-9293-756X
Attar Shahinaz El shahinazattar@gmail.com

5
1 https://ror.org/05fnp1145 grid.411303.4 0000 0001 2155 6022 Endocrinology and Metabolism Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
2 https://ror.org/05fnp1145 grid.411303.4 0000 0001 2155 6022 Internal Medicine Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
3 https://ror.org/05fnp1145 grid.411303.4 0000 0001 2155 6022 Rheumatology and Rehabilitation Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
4 https://ror.org/05fnp1145 grid.411303.4 0000 0001 2155 6022 Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
5 https://ror.org/05fnp1145 grid.411303.4 0000 0001 2155 6022 Medical Biochemistry and Molecular Biology Department, Faculty of Medicine for Girls, Al- Azhar University, Cairo, Egypt
5 9 2024
5 9 2024
2024
24 49022 5 2024
12 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Osteoporosis (OP) is a common finding in diabetic patients especially high-risk populations such as postmenopausal women. Sclerostin is a glycoprotein chiefly secreted by mature osteocytes and is considered a main regulator of bone formation. The C1q/TNF-Related Protein 3 (CTRP3) was found to be significantly associated with OP in postmenopausal women. The effect of type 2 diabetes mellitus (T2DM) on sclerostin and CTRP3 levels in postmenopausal women is rarely investigated. The present study aimed to assess the impact of T2DM on sclerostin and CTRP3 levels and their relation to OP in postmenopausal women.

Methods

The study included 60 postmenopausal women with T2DM and 60 age-matched postmenopausal non-diabetic women. Bone mineral density (BMD) was assessed using dual energy X-ray absorptiometry (DEXA). Serum levels of sclerostin and CTRP3 were assessed using enzyme-linked immunosorbent assay (ELISA) technique.

Results

Diabetic group expressed significantly higher serum levels of sclerostin when compared with non-diabetic group (110.0 ± 29.0 versus 51.5 ± 23.2 ng; p < 0.001). Oppositely, CTRP3 were significantly lower in the diabetic group (3.5 ± 3.5 versus 9.9 ± 3.7 ng/ml, p < 0.001). Multivariate logistic regression analysis identified HbA1c levels [OR (95% CI): 0.49 (0.26–0.93), p = 0.028], sclerotin levels [OR (95% CI): 1.06 (1.0-1.012), p = 0.041] and CTRP3 levels [OR (95%) CI: 1.64 (1.0-2.68), p = 0.047] as significant predictors of OP in diabetic patients.

Conclusions

Sclerostin and CTRP3 levels are involved in OP in postmenopausal diabetic patients.

Keywords

Type 2 diabetes mellitus
Osteoporosis
CTRP3
Sclerostin
Al-Azhar UniversityOpen access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Type 2 diabetes mellitus (T2DM) is one of the most prevalent non-communicable diseases worldwide that substantially increase the risk of cardiovascular diseases, angiopathies, and various metabolic disorders [1–4]. Osteoporosis (OP) is a common finding in diabetic patients [5], especially high-risk populations such as postmenopausal women [6].

Sclerostin is a glycoprotein chiefly secreted by mature osteocytes and is considered a main regulator of bone formation through its effect on Wnt signaling [7] making its circulating level a promising biomarker for the diagnosis and prognosis of OP [8]. However, previous studies presented controversial results regarding the relation between sclerostin levels and OP [9–11].

In diabetic patients, the adipose tissue plays a vital role by secreting bioactive molecules called adipokines [12]. The chronic low-grade inflammation mediated by adipokines was shown as a potential therapeutic target for management of diabetic complications [13]. For instance, circulating levels of adiponectin are downregulated in T2DM patients. It is considered as the most beneficial adipokine in circulation, improving insulin sensitivity, endothelial functions, and inflammation [14].

The C1q/TNF-Related Protein (CTRP) family members are paralogues of adiponectin. They share favorable effects on inflammation, insulin sensitivity, and lipid metabolism [15]. Several studies observed the association between expression of CTRP family members and diabetes, coronary artery diseases, metabolic syndrome, non-alcoholic fatty liver disease, and polycystic ovary syndrome [16–18]. CTRP3 activates adenosine monophosphate-activated protein kinase (AMPK), thus enhancing insulin signaling and sensitivity [19]. Decline of circulating CTRP3 levels was linked to insulin resistance in diabetic patients and rise of its levels was noted after treatment with glucagon-like peptide-1 (GLP-1) receptor agonists [20]. Recently, serum CTRP3 was found to be significantly associated with OP in postmenopausal women [21]. The effect of T2DM on sclerostin and CTRP3 levels in postmenopausal women is rarely investigated. The present study aimed to assess the impact of T2DM) on sclerostin and CTRP3 levels and their relation to OP in postmenopausal women.

Methods

The present cross-sectional study was conducted at Al-Azhar University Hospitals, Cairo, Egypt. The study protocol was approved by the local ethical committee and all participants provided informed consent before enrollment. The study included 60 postmenopausal women with T2DM and 60 age-matched postmenopausal non-diabetic women. Menopause was identified through a history of menstruation cessation for at least one year prior to enrollment. The diagnosis of T2DM was based on the criteria of the American Diabetes Association (ADA) [22]. We excluded women with diabetic nephropathy, morbid obesity, familial dyslipidemia, organ failure, malignancies, thyroid disorder, history of hormonal therapy, and/or associated immunological disorders. Patients were also excluded if they received medications known to impair bone metabolism e.g. thiazolidinediones or if they were under OP treatment.

Patients included in the study were submitted to careful history taking and through clinical examination. For biochemical assessment, 10 ml of venous blood were obtained from each participant after 8-hour fasting. Each collected sample was divided into two parts; 7 ml part for routine investigations and the other part was centrifuged for 10 min at 4000 rpm and was stored at – 80 ° C. Colorimetric enzymatic approaches were used for estimation of the lipid profile and blood glucose profile using Hitachi autoanalyzer 704 (Roche Diagnostics. Switzerland).

Automated Glycohemoglobin Analyzer (Tosoh Bioscience’s HLC-723GX@, Tosoh, India) was used to estimate the HbA1c in blood. Chemiluminescent immunoassay (Immulite2000, Siemens, Germany) was utilized to assess serum insulin form blood samples. The following formula was used to estimate HOMA-IR: HOMA-IR = fasting insulin (IU/mL) × plasma glucose (mg/dL)/405 [23].

Automated ELIZA (Thermo Scientific, Finland) and computer program (Scanlt for Multiscan FC 2.5.1) were used to measure serum levels of CTRP3. The device was set for CTRP3 sensitivity of 0.38 ng/ml. Serum sclerostin levels were assessed utilizing quantitative sandwich ELISA (Biomedica, Vienna, Austria).

Bone mineral density (BMD) was assessed through dual energy X-ray absorptiometry (Lunar Prodigy; General Electric Medical Systems; USA) at the level of the femur neck and L2-L4 spines. The diagnosis of OP was based on the findings of BMD, in which a T-score of less than − 2.5 was used as a cutoff value for the presence of OP; while a T-score ranging from − 1 to -2.5 was used a definition of osteopenia.

Data analysis was conducted by SPSS software, version 22.0 (SPSS Inc., Chicago, Illinois, USA). Numerical variables were expressed as number and percent and compared using t test while categorical data were presented as number and percent and compared using Fisher’s exact test or Chi-square test as appropriate. Correlation analysis was achieved using Pearson’s correlation coefficient. Binary logistic regression was used to identify predictors of OP. p value less than 0.05 was considered statistically significant.

Results

The present study included 60 diabetic postmenopausal women and 60 age matched postmenopausal non-diabetic women. Clinical findings in the studied groups are shown in tabl-1. Diabetic group expressed significantly higher serum levels of sclerostin when compared with non-diabetic group (110.0 ± 29.0 versus 51.5 ± 23.2 ng, p < 0.001). Oppositely, CTRP3 were significantly lower in the diabetic group (3.5 ± 3.5 versus 9.9 ± 3.7 ng/ml, p < 0.001). BMD analysis identified osteopenia and OP in 30.0% and 46.7% respectively in the diabetic group while in the non-diabetic group, osteopenia and OP were identified in 25.0% and 25.0% of women respectively (p = 0.007) (Table 1).

Table 1 Comparison between groups according to demographic and laboratory data

	Diabetic group
n = 60	Non-diabetic group
n = 60	p-value	
Age years	53.4 ± 7.7	56.1 ± 1.5	0.102	
SBP mmHg	125.3 ± 15.0	112.3 ± 4.3	< 0.001	
DBP mmHg	81.3 ± 10.1	73.7 ± 4.9	< 0.001	
BMI kg/m2	33.5 ± 4.6	29.1 ± 3.0	< 0.001	
FBS mg/dL	207.0 ± 68.0	89.2 ± 8.0	< 0.001	
PPBS mg/dL	261.7 ± 88.0	122.2 ± 11.7	< 0.001	
HbA1c %	9.0 ± 2.0	5.4 ± 0.3	< 0.001	
Cholesterol mg/dL	207.3 ± 49.2	182.6 ± 23.6	< 0.001	
Triglycerides mg/dL	168.5 ± 62.7	119.2 ± 20.5	< 0.001	
HDL mg/dL	38.7 ± 5.8	36.9 ± 6.4	0.004	
LDL mg/dL	139.4 ± 44.8	122.8 ± 21.3	< 0.001	
Insulin IU/mL	15.4 ± 5.8	6.9 ± 1.5	< 0.001	
HOMA-IR	6.6 ± 2.1	1.5 ± 0.4	< 0.001	
Sclerostin ng/ml	110.0 ± 29.0	51.5 ± 23.2	< 0.001	
CTRP3 ng/ ml	3.5 ± 3.5	9.9 ± 3.7	< 0.001	
DEXA scan n (%)	
Normal	14 (23.3)	30 (50.0)	0.007	
Osteopenia	18 (30.0)	15 (25.0)	
Osteoporosis	28 (46.7)	15 (25.0)	
BMI: Body mass index, CTRP3: C1q/TNF-Related Protein 3, DBP: Diastolic blood pressure, DEXA: dual energy X-ray absorptiometry, FBS: Fasting blood sugar, HDL: High-density lipoprotein, HOMA-IR: Homeostatic model assessment for insulin resistance, LDL: Low-density lipoprotein, PPBS: Postprandial blood sugar, SBP: Systolic blood pressure

In the diabetic group, correlation analysis identified significant correlation between serum CTRP3 levels and age (r = 0.369, p = 0.045), SBP (r = 0.369, p = 0.045), DBP (r = 0.328, p = 0.037) and insulin (r = 0.612, p = 0.009). Also, there were significant correlations between serum sclerostin levels and HbA1c (r=-0.307, p = 0.049) and HOMA-IR (p=-0.732, p < 0.001). In the non-diabetic group, there were significant correlations between serum CTRP3 levels and age (r = 0.683, p < 0.001), SBP (r = 0.557, p < 0.001), FBS (r = 0.632, p < 0.001), HbA1c (r=-0.460, p = 0.011), HDL (r = 0.721, p < 0.001), LDL (r=-0.477, p = 0.008), insulin (r = 0.466, p = 0.010) and HOMA-IR (r = 0.611, p < 0.001). Also, there were significant correlations between sclerotin levels and age (r=-0.392, p = 0.032), DBP (r=-0.411, p = 0.024), FBS (r=-0.723, p < 0.001), PPBS (r=-0.510, p = 0.004), cholesterol (r = 0.40, p = 0.028), HDL (r=-0.680, p < 0.001), LDL (r = 0.548, p = 0.002) and HOMA-RI (r=-0.399, p = 0.029) (Table 2).

Table 2 Correlation between CTRP3 and sclerostin levels and clinical data

	Diabetic group	Non-diabetic group	
CTRP3	Sclerostin	CTRP3	Sclerostin	
r	p-value	r	p-value	r	p-value	r	p-value	
Age (years)	0.369	0.045	0.095	0.619	0.683	< 0.001	-0.392	0.032	
BMI	0.260	0.166	0.004	0.983	-0.300	0.107	0.055	0.773	
Disease duration	-0.302	0.105	-0.009	0.964	-	-	-	-	
SBP	0.369	0.045	0.171	0.367	0.557	< 0.001	-0.220	0.243	
DBP	0.328	0.037	0.132	0.487	0.207	0.273	-0.411	0.024	
FBS	0.137	0.470	-0.205	0.277	0.632	< 0.001	-0.723	< 0.001	
PPBS	0.013	0.947	-0.131	0.490	0.207	0.271	-0.510	0.004	
HbA1c	0.010	0.957	-0.307	0.049	-0.460	0.011	0.113	0.552	
Cholesterol	-0.112	0.554	-0.075	0.693	-0.248	0.186	0.400	0.028	
Triglycerides	0.121	0.525	0.059	0.757	0.122	0.519	0.042	0.827	
HDL	0.060	0.753	-0.106	0.577	0.721	< 0.001	-0.680	< 0.001	
LDL	-0.232	0.217	0.012	0.951	-0.477	0.008	0.548	0.002	
Insulin	0.612	0.009	-0.286	0.265	0.466	0.010	-0.174	0.356	
HOMA-IR	0.046	0.859	-0.732	< 0.001	0.611	< 0.001	-0.399	0.029	

Multivariate logistic regression analysis identified HbA1c levels [OR (95% CI): 0.49 (0.26–0.93), p = 0.028], sclerotin levels [OR (95% CI): 1.06 (1.0-1.012), p = 0.041] and CTRP3 levels [OR (95%) CI: 1.64 (1.0-2.68), p = 0.047] as significant predictors of OP in diabetic patients (Table 3).

Table 3 Predictors of osteoporosis in diabetic patients

	Univariate analysis	Multivariate analysis	
OR	95% CI	p value	OR	95% CI	p value	
Age	1.16	1.04–1.31	0.011	1.12	0.87–1.45	0.36	
Disease duration	1.21	1.08–1.35	0.001	1.09	0.87–1.36	0.46	
HbA1c	0.53	0.38–0.75	< 0.001	0.49	0.26–0.93	0.028	
Sclerostin	1.06	1.03–1.1	< 0.001	1.06	1.0-1.012	0.041	
CTRP3	2.07	1.41–3.03	< 0.001	1.64	1.0-2.68	0.047	

Discussion

While the current published literature demonstrates significant association between the serum sclerostin and CTRP3 with OP, little is known about the additional impact of T2DM on these biomarkers. In the present study, multivariate logistic regression analysis identified sclerotin levels and CTRP3 levels as significant predictors of OP in diabetic patients.

Recently, emerging evidence highlighted a significant role of serum CTRP3 in regulation of bone hemostasis; the role of CTRP3 in regulation of bone structure appears to stem from its ability to maintain normal turnover of chondrocytes and cartilaginous structure through regulation of ERK1/2 and PI3K pathways [24, 25]. Thus, authors linked downregulation of serum CTRP3 to defective bone metabolism and features of OP [26]. On the other hand, the association between CTRP3 and T2DM is well-established with reported decline in serum CTRP3 levels among cases with insulin resistance and poor glycemic control [20]. Our analysis demonstrated that serum CTRP3 was independent predictor of OP in T2DM women and correlated significantly with metabolic parameters. To our knowledge, this is the first report that addressed the impact of T2DM on serum CTRP3 among women with OP.

The impact of T2DM on CTRP3 levels can be mediated through multiple mechanisms. Previous studies found an association between dyslipidemia and reduced CTRP3 levels in diabetic patients [27, 28]. Also, experimental evidence suggests a link between increased oxidative stress and inflammation related to the diabetic state and low levels of CTRP3 [29–31]. Importantly, the study of Wagner et al. [32] found that only female diabetic patients had reduced CTRP3 levels suggesting a possible relation between circulating CTRP3 levels and the hormonal status.

Sclerostin is usually secreted by osteocytes and late osteoblasts to mediate physiological bone metabolism [33]. The changes in the levels of circulating sclerostin may reflect the changes in bone activity, making it a biomarker for the diagnosis and prognosis of OP [34]. On the other hand, previous animal models demonstrated high expression of sclerostin gene, SOST, in the setting of T2DM [35]. Thus, it is logical to assume higher degree of dysregulated levels of sclerostin in patients with combined T2DM and OP. We found that serum sclerostin is a significant predictor of OP in diabetic women. In support of our conclusions, Wang and colleagues [36] showed that the combination of T2DM and OP led to higher increase in serum sclerostin than OP alone; moreover, serum sclerostin correlated with BMD parameters, HbA1c, and serum glucose level. The increased levels of sclerostin levels in diabetic patients are related to higher oxidative stress [37], poor glycemic control [38] and some genetic polymorphisms [39].

In the present study, we acknowledge the presence of some methodological limitations. The cross-sectional nature of the present study limits the validity of the observed associations and further long-term studies are still needed to confirm the sequential role of T2DM on osteoporosis biomarkers. In addition, the lack of pre-planned samples size calculation and being a single-center experience are additional limitations of the present study.

Conclusions

In conclusion, the present study provides novel evidence about the impact of T2DM on OP biomarkers, serum CTRP3 and sclerostin. The results indicated that women with combined T2DM and OP/osteopenia exhibited more dysregulation in both biomarkers than non-diabetic women. Thus, serum CTRP3 and sclerostin can be used as biomarkers for early detection of OP in diabetic patients. Further experiments are warranted to confirm our findings and to understand the mechanistic processes behind the additional impact of T2DM on the OP biomarkers. In addition, further investigations about the link between adipose tissue and bone hemostasis are recommended.

Acknowledgements

We heartfully thank all patients who participated in this study.

Author contributions

Conceptualization: IHA, SSAG, BMMAE, MKA, EOAE, DSM, MAM, MSM, MMMAA, SE; patients’ recruitment: IHA, SSAG, BMMAE, MKA, EOAE, DSM, MAM, MSM, MMMAA, SE data acquisition and analysis: IHA, SSAG, BMMAE, MKA, EOAE, DSM, MAM, MSM, MMMAA, SE; manuscript drafting and writing: IHA, SSAG, BMMAE, MKA, EOAE, DSM, MAM, MSM, MMMAA, SE. All authors revised the final manuscript.

Funding

None.

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Protocol of the present study was approved by the ethical committee of Al-Azhar Faculty of Medicine and all participants provided informed consent in accordance with the Helsinki Declaration on clinical research involving human subjects.

Consent for publication

NA.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular Complications of Type 2 Diabetes Mellitus. Curr Vasc Pharmacol. 2020;18(2):110–16. 10.2174/1570161117666190405165151. PMID: 30961498.
2. Horton WB Barrett EJ Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease Endocr Rev 2021 42 1 29 55 10.1210/endrev/bnaa025 33125468
Horton WB, Barrett EJ. Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease. Endocr Rev. 2021;42(1):29–55. 10.1210/endrev/bnaa025. PMID: 33125468; PMCID: PMC7846151.33125468 10.1210/endrev/bnaa025
3. Triposkiadis F Xanthopoulos A Bargiota A Kitai T Katsiki N Farmakis D Skoularigis J Starling RC Iliodromitis E Diabetes Mellitus and Heart failure J Clin Med 2021 10 16 3682 10.3390/jcm10163682 34441977
Triposkiadis F, Xanthopoulos A, Bargiota A, Kitai T, Katsiki N, Farmakis D, Skoularigis J, Starling RC, Iliodromitis E. Diabetes Mellitus and Heart failure. J Clin Med. 2021;10(16):3682. 10.3390/jcm10163682. PMID: 34441977; PMCID: PMC8396967.34441977 10.3390/jcm10163682
4. Kane JP Pullinger CR Goldfine ID Malloy MJ Dyslipidemia and Diabetes Mellitus: role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus Curr Opin Pharmacol 2021 61 21 7 10.1016/j.coph.2021.08.013 34562838
Kane JP, Pullinger CR, Goldfine ID, Malloy MJ. Dyslipidemia and Diabetes Mellitus: role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus. Curr Opin Pharmacol. 2021;61:21–7. Epub 2021 Sep 22. PMID: 34562838.34562838 10.1016/j.coph.2021.08.013
5. Brandt IAG Starup-Linde J Andersen SS Viggers R Diagnosing osteoporosis in Diabetes-A systematic review on BMD and fractures Curr Osteoporos Rep 2024 22 2 223 44 10.1007/s11914-024-00867-1 38509440
Brandt IAG, Starup-Linde J, Andersen SS, Viggers R. Diagnosing osteoporosis in Diabetes-A systematic review on BMD and fractures. Curr Osteoporos Rep. 2024;22(2):223–44. 10.1007/s11914-024-00867-1. Epub 2024 Mar 21. PMID: 38509440.38509440 10.1007/s11914-024-00867-1
6. Ali D Tencerova M Figeac F Kassem M Jafari A The pathophysiology of osteoporosis in obesity and type 2 diabetes in aging women and men: the mechanisms and roles of increased bone marrow adiposity Front Endocrinol (Lausanne) 2022 13 981487 10.3389/fendo.2022.981487 36187112
Ali D, Tencerova M, Figeac F, Kassem M, Jafari A. The pathophysiology of osteoporosis in obesity and type 2 diabetes in aging women and men: the mechanisms and roles of increased bone marrow adiposity. Front Endocrinol (Lausanne). 2022;13:981487. 10.3389/fendo.2022.981487. PMID: 36187112; PMCID: PMC9520254.36187112 10.3389/fendo.2022.981487
7. Omran A Atanasova D Landgren F Magnusson P Sclerostin From molecule to clinical biomarker Int J Mol Sci 2022 23 9 4751 10.3390/ijms23094751 35563144
Omran A, Atanasova D, Landgren F, Magnusson P, Sclerostin. From molecule to clinical biomarker. Int J Mol Sci. 2022;23(9):4751. 10.3390/ijms23094751. PMID: 35563144; PMCID: PMC9104784.35563144 10.3390/ijms23094751
8. Anastasilakis AD, Tsourdi E. Τhe story of sclerostin inhibition: the past, the present, and the future. Hormones (Athens). 2024 Jan 3. 10.1007/s42000-023-00521-y. Epub ahead of print. PMID: 38170438.
9. Starup-Linde J Lykkeboe S Gregersen S Hauge EM Langdahl BL Handberg A Vestergaard P Bone structure and predictors of fracture in type 1 and type 2 diabetes J Clin Endocrinol Metab 2016 101 3 928 36 10.1210/jc.2015-3882 26756117
Starup-Linde J, Lykkeboe S, Gregersen S, Hauge EM, Langdahl BL, Handberg A, Vestergaard P. Bone structure and predictors of fracture in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2016;101(3):928–36. 10.1210/jc.2015-3882. Epub 2016 Jan 12. PMID: 26756117.26756117 10.1210/jc.2015-3882
10. Yamamoto M Yamauchi M Sugimoto T Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus J Clin Endocrinol Metab 2013 98 10 4030 7 10.1210/jc.2013-2143 23894157
Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(10):4030–7. 10.1210/jc.2013-2143. Epub 2013 Jul 26. PMID: 23894157.23894157 10.1210/jc.2013-2143
11. Ardawi MS Akhbar DH Alshaikh A Ahmed MM Qari MH Rouzi AA Ali AY Abdulrafee AA Saeda MY Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes Bone 2013 56 2 355 62 10.1016/j.bone.2013.06.029 23845326
Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013;56(2):355–62. Epub 2013 Jul 9. PMID: 23845326.23845326 10.1016/j.bone.2013.06.029
12. Sakaguchi M Adipose tissue plasticity and insulin signaling in the pathogenesis of type 2 diabetes Diabetol Int 2023 15 1 28 33 10.1007/s13340-023-00676-4 38264220
Sakaguchi M. Adipose tissue plasticity and insulin signaling in the pathogenesis of type 2 diabetes. Diabetol Int. 2023;15(1):28–33. 10.1007/s13340-023-00676-4. PMID: 38264220; PMCID: PMC10800324.38264220 10.1007/s13340-023-00676-4
13. Bahadoran Z, Mirmiran P, Ghasemi A. Adipose organ dysfunction and type 2 diabetes: Role of nitric oxide. Biochem Pharmacol. 2024;221:116043. 10.1016/j.bcp.2024.116043. Epub 2024 Feb 5. PMID: 38325496.
14. Begum M Choubey M Tirumalasetty MB Arbee S Mohib MM Wahiduzzaman M Mamun MA Uddin MB Mohiuddin MS Adiponectin: a Promising Target for the treatment of diabetes and its complications Life (Basel) 2023 13 11 2213 10.3390/life13112213 38004353
Begum M, Choubey M, Tirumalasetty MB, Arbee S, Mohib MM, Wahiduzzaman M, Mamun MA, Uddin MB, Mohiuddin MS. Adiponectin: a Promising Target for the treatment of diabetes and its complications. Life (Basel). 2023;13(11):2213. 10.3390/life13112213. PMID: 38004353; PMCID: PMC10672343.38004353 10.3390/life13112213
15. Guo B Zhuang T Xu F Lin X Li F Shan SK Wu F Zhong JY Wang Y Zheng MH Xu QS Ehsan UMH Yuan LQ New insights into implications of CTRP3 in obesity, metabolic dysfunction, and Cardiovascular diseases: potential of therapeutic interventions Front Physiol 2020 11 570270 10.3389/fphys.2020.570270 33343381
Guo B, Zhuang T, Xu F, Lin X, Li F, Shan SK, Wu F, Zhong JY, Wang Y, Zheng MH, Xu QS, Ehsan UMH, Yuan LQ. New insights into implications of CTRP3 in obesity, metabolic dysfunction, and Cardiovascular diseases: potential of therapeutic interventions. Front Physiol. 2020;11:570270. 10.3389/fphys.2020.570270. PMID: 33343381; PMCID: PMC7744821.33343381 10.3389/fphys.2020.570270
16. Fadaei R Moradi N Baratchian M Aghajani H Malek M Fazaeli AA Fallah S Association of C1q/TNF-Related Protein-3 (CTRP3) and CTRP13 serum levels with coronary artery disease in subjects with and without type 2 diabetes Mellitus PLoS ONE 2016 11 12 e0168773 10.1371/journal.pone.0168773 28033351
Fadaei R, Moradi N, Baratchian M, Aghajani H, Malek M, Fazaeli AA, Fallah S. Association of C1q/TNF-Related Protein-3 (CTRP3) and CTRP13 serum levels with coronary artery disease in subjects with and without type 2 diabetes Mellitus. PLoS ONE. 2016;11(12):e0168773. 10.1371/journal.pone.0168773. PMID: 28033351; PMCID: PMC5199067.28033351 10.1371/journal.pone.0168773
17. Fadaei R, Moradi N, Kazemi T, Chamani E, Azdaki N, Moezibady SA, Shahmohamadnejad S, Fallah S. Decreased serum levels of CTRP12/adipolin in patients with coronary artery disease in relation to inflammatory cytokines and insulin resistance. Cytokine. 2019;113:326–31. 10.1016/j.cyto.2018.09.019. Epub 2018 Oct 15. PMID: 30337217.
18. Shanaki M Moradi N Fadaei R Zandieh Z Shabani P Vatannejad A Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome: irrespective of obesity PLoS ONE 2018 13 12 e0208059 10.1371/journal.pone.0208059 30540803
Shanaki M, Moradi N, Fadaei R, Zandieh Z, Shabani P, Vatannejad A. Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome: irrespective of obesity. PLoS ONE. 2018;13(12):e0208059. 10.1371/journal.pone.0208059. PMID: 30540803; PMCID: PMC6291267.30540803 10.1371/journal.pone.0208059
19. Yaribeygi H, Rashidfarrokhi F, Atkin SL, Sahebkar A. C1q/TNF-related protein-3 and glucose homeostasis. Diabetes Metab Syndr. 2019 May-Jun;13(3):1923–7. 10.1016/j.dsx.2019.04.047. Epub 2019 Apr 25. PMID: 31235116.
20. Li X Jiang L Yang M Wu Y Sun S Sun J GLP-1 receptor agonist increases the expression of CTRP3, a novel adipokine, in 3T3-L1 adipocytes through PKA signal pathway J Endocrinol Invest 2015 38 1 73 9 10.1007/s40618-014-0156-8 25149084
Li X, Jiang L, Yang M, Wu Y, Sun S, Sun J. GLP-1 receptor agonist increases the expression of CTRP3, a novel adipokine, in 3T3-L1 adipocytes through PKA signal pathway. J Endocrinol Invest. 2015;38(1):73–9. 10.1007/s40618-014-0156-8. Epub 2014 Aug 23. PMID: 25149084.25149084 10.1007/s40618-014-0156-8
21. Zhang XJ, Zhang D, Qin J, Zhou YR, Guo JL, Zhang YZ. Serum CTRP3 concentrations are positively correlated with disease severity in women with postmenopausal osteoporosis: a population-based cross-sectional study. Eur Rev Med Pharmacol Sci. 2023;27(22):10868–74. 10.26355/eurrev_202311_34454. PMID: 38039016.
22. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13-S28. 10.2337/dc19-S002. PMID: 30559228.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. 10.1007/BF00280883. PMID: 3899825.
24. Maeda T Abe M Kurisu K Jikko A Furukawa S Molecular cloning and characterization of a novel gene, CORS26, encoding a putative secretory protein and its possible involvement in skeletal development J Biol Chem 2001 276 5 3628 34 10.1074/jbc.M007898200 11071891
Maeda T, Abe M, Kurisu K, Jikko A, Furukawa S. Molecular cloning and characterization of a novel gene, CORS26, encoding a putative secretory protein and its possible involvement in skeletal development. J Biol Chem. 2001;276(5):3628–34. 10.1074/jbc.M007898200. Epub 2000 Nov 8. PMID: 11071891.11071891 10.1074/jbc.M007898200
25. Maeda T, Jikko A, Abe M, Yokohama-Tamaki T, Akiyama H, Furukawa S, Takigawa M, Wakisaka S. Cartducin, a paralog of Acrp30/adiponectin, is induced during chondrogenic differentiation and promotes proliferation of chondrogenic precursors and chondrocytes. J Cell Physiol. 2006;206(2):537 – 44. 10.1002/jcp.20493. PMID: 16155912.
26. Musso G Paschetta E Gambino R Cassader M Molinaro F Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver Trends Mol Med 2013 19 9 522 35 10.1016/j.molmed.2013.05.006 23816817
Musso G, Paschetta E, Gambino R, Cassader M, Molinaro F. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med. 2013;19(9):522–35. 10.1016/j.molmed.2013.05.006. Epub 2013 Jun 28. PMID: 23816817.23816817 10.1016/j.molmed.2013.05.006
27. Elsaid HH, Elgohary MN, Elshabrawy AM. Complement c1q tumor necrosis factor-related protein 3 a novel adipokine, protect against diabetes mellitus in young adult Egyptians. Diabetes Metab Syndr. 2019 Jan-Feb;13(1):434–38. 10.1016/j.dsx.2018.10.004. Epub 2018 Oct 12. PMID: 30641739.
28. Trogen G Alamian A Peterson JM High molecular weight, but not total, CTRP3 levels are associated with serum triglyceride levels Physiol Rep 2019 7 23 e14306 10.14814/phy2.14306 31814309
Trogen G, Alamian A, Peterson JM. High molecular weight, but not total, CTRP3 levels are associated with serum triglyceride levels. Physiol Rep. 2019;7(23):e14306. 10.14814/phy2.14306. PMID: 31814309; PMCID: PMC6900490.31814309 10.14814/phy2.14306
29. Ma ZG, Yuan YP, Xu SC, Wei WY, Xu CR, Zhang X, Wu QQ, Liao HH, Ni J, Tang QZ. CTRP3 attenuates cardiac dysfunction, inflammation, oxidative stress and cell death in diabetic cardiomyopathy in rats. Diabetologia. 2017;60(6):1126–37. 10.1007/s00125-017-4232-4. Epub 2017 Mar 3. PMID: 28258411.
30. Zhang J, He J. CTRP3 inhibits high glucose-induced oxidative stress and apoptosis in retinal pigment epithelial cells. Artif Cells Nanomed Biotechnol. 2019;47(1):3758–64. 10.1080/21691401.2019.1666864. PMID: 31556307.
31. Zeng X Peng Y Wang Y Kang K C1q/tumor necrosis factor-related protein-3 (CTRP3) activated by forkhead box O4 (FOXO4) down-regulation protects retinal pericytes against high glucose-induced oxidative damage through nuclear factor erythroid 2-related factor 2 (Nrf2)/Nuclear factor-kappab (NF-κB) signaling Bioengineered 2022 13 3 6080 91 10.1080/21655979.2022.2031413 35196182
Zeng X, Peng Y, Wang Y, Kang K. C1q/tumor necrosis factor-related protein-3 (CTRP3) activated by forkhead box O4 (FOXO4) down-regulation protects retinal pericytes against high glucose-induced oxidative damage through nuclear factor erythroid 2-related factor 2 (Nrf2)/Nuclear factor-kappab (NF-κB) signaling. Bioengineered. 2022;13(3):6080–91. PMID: 35196182; PMCID: PMC8974204.35196182 10.1080/21655979.2022.2031413
32. Wagner RM Sivagnanam K Clark WA Peterson JM Divergent relationship of circulating CTRP3 levels between obesity and gender: a cross-sectional study PeerJ 2016 4 e2573 10.7717/peerj.2573 27781167
Wagner RM, Sivagnanam K, Clark WA, Peterson JM. Divergent relationship of circulating CTRP3 levels between obesity and gender: a cross-sectional study. PeerJ. 2016;4:e2573. 10.7717/peerj.2573. PMID: 27781167; PMCID: PMC5075694.27781167 10.7717/peerj.2573
33. Voorzanger-Rousselot N Journe F Doriath V Body JJ Garnero P Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases Calcif Tissue Int 2009 84 5 348 54 10.1007/s00223-009-9225-y 19252761
Voorzanger-Rousselot N, Journe F, Doriath V, Body JJ, Garnero P. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases. Calcif Tissue Int. 2009;84(5):348–54. 10.1007/s00223-009-9225-y. Epub 2009 Feb 28. PMID: 19252761.19252761 10.1007/s00223-009-9225-y
34. Drake MT Srinivasan B Mödder UI Peterson JM McCready LK Riggs BL Dwyer D Stolina M Kostenuik P Khosla S Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women J Clin Endocrinol Metab 2010 95 11 5056 62 10.1210/jc.2010-0720 20631014
Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95(11):5056–62. 10.1210/jc.2010-0720. Epub 2010 Jul 14. PMID: 20631014; PMCID: PMC2968729.20631014 10.1210/jc.2010-0720
35. Nuche-Berenguer B, Moreno P, Portal-Nuñez S, Dapía S, Esbrit P, Villanueva-Peñacarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept. 2010;159(1–3):61 – 6. 10.1016/j.regpep.2009.06.010. PMID: 19586609.
36. Wang N, Xue P, Wu X, Ma J, Wang Y, Li Y. Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients. Endocr Res. 2018;43(1):29–38. doi: 10.1080/07435800.2017.1373662. Epub 2017 Oct 3. PMID: 28972408.
37. Sabancilar I, Unsal V, Demir F, Toprak G, Pekkolay Z. Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? Folia Med (Plovdiv). 2023;65(1):46–52. 10.3897/folmed.65.e72953. PMID: 36855973.
38. Singh PK Naithani M Pathania M Mirza AA Saha S An Insight into the Association of Sclerostin with Insulin Sensitivity and glycemic parameters in male Indian Prediabetic and Diabetic Population Cureus 2022 14 7 e27123 10.7759/cureus.27123 36004027
Singh PK, Naithani M, Pathania M, Mirza AA, Saha S. An Insight into the Association of Sclerostin with Insulin Sensitivity and glycemic parameters in male Indian Prediabetic and Diabetic Population. Cureus. 2022;14(7):e27123. 10.7759/cureus.27123. PMID: 36004027; PMCID: PMC9392653.36004027 10.7759/cureus.27123
39. Li J Ren Y Li S Li J Relationship between sclerostin (SOST) expression and genetic loci rs851056, rs1230399 polymorphisms and bone Mineral Density in Postmenopausal Women with type 2 diabetes in Xinjiang Diabetes Metab Syndr Obes 2021 14 4443 50 10.2147/DMSO.S305831 34764662
Li J, Ren Y, Li S, Li J. Relationship between sclerostin (SOST) expression and genetic loci rs851056, rs1230399 polymorphisms and bone Mineral Density in Postmenopausal Women with type 2 diabetes in Xinjiang. Diabetes Metab Syndr Obes. 2021;14:4443–50. PMID: 34764662; PMCID: PMC8575445.34764662 10.2147/DMSO.S305831
